By Orjana Terova, John Li, Jessica de Rooij, Pim Hermans, Alejandro Becerra and Frank Detmers; Thermo Fisher Scientific
Over the past decade, gene therapy applications and their importance in the biopharmaceutical industry have been increasing. The non-pathogenic adeno-associated virus (AAV) has emerged as the vector of choice for many therapies but purification of biologically active viral vectors for large-scale commercial use is a challenge. Thermo Fisher Scientific has developed downstream purification solutions, enabling the scale-up of viral vector production.
VIRAL VECTOR PURIFICATION CHALLENGES
- Multiple chromatography steps & concentration needed due to challenging feedstock
- Long process development lead times
- Cumulative yield losses with each unit operation